CompletedPhase 3NCT00864383

Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis

Studying Primary pulmonary tuberculosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Global Alliance for TB Drug Development
Principal Investigator
Stephen H Gillespie, MB BCh BAO MD DSc
University of St Andrews
Intervention
Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin(drug)
Enrollment
1931 enrolled
Eligibility
18 years · All sexes
Timeline
20082014

Study locations (30)

Collaborators

European and Developing Countries Clinical Trials Partnership (EDCTP) · University College, London · Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma · Sanofi

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00864383 on ClinicalTrials.gov

Other trials for Primary pulmonary tuberculosis

Additional recruiting or active studies for the same condition.

See all trials for Primary pulmonary tuberculosis

← Back to all trials